ARCHIVES

Patient Groups Are Focus of New Alliances In a Shift of Cancer Advocacy Agenda

This article is from The Cancer Letter archive.

Vol. 22 No. 22 | May 31, 1996

Download PDF Visit The Full Archive

Related Articles

In Brief: James Institute Receives $9 Million Gift; NCI’s Fraumeni Wins Public Health Award

November 3, 1995

Vectibix Non-Inferior to Erbitux In Wild-Type Metastatic Disease

October 25, 2013

Group Chairman Present A Counter-Proposal To NCI Committee

June 12, 1998

M.D. Anderson Closes Trials following FDA Requests for Data

February 16, 1996

Congressional Panel Is Investigating FDA Oversight Of Generic Cancer Drugs

August 18, 1995

Rumors Preceded Broder’s Move

December 22, 1994